A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and…
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with…
MYELOMA
Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate…
MYELOMA
Switching Chemo Types in Initial Combo May Help Myeloma Patients with Poor Response, Study Says
For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another…
People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to…
A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a…
Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and…
The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the…
People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can…